Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.

Journal of oncology practice - 1 Apr 2017

Bernicker Eric H, Miller Ross A, Cagle Phillip T

Abstract excerpt

To suggest that the discovery of targetable driver mutations in many patients with advanced adenocarcinoma of the lung has completely transformed the work-up and therapeutic options for this disease would not be hyperbole. Although not curative, small-molecule tyrosine kinase inhibitors directed at oncogene-addicted tumors have led to significantly improved response rates compared with cytotoxic chemotherapy,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Anaplastic Lymphoma Kinase
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Diagnostic Techniques

Share to Molecular Targeted Therapy

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 28399384
DOI: 10.1200/JOP.2016.019182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.PMID 28399384Read ↗

Molecular biomarkers for lung adenocarcinoma.Semantic proximity Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

Biomarkers in lung adenocarcinoma: a decade of progress.Semantic proximity Read ↗

Importance of molecular features of non-small cell lung cancer for choice of treatment.Semantic proximity Read ↗

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.Semantic proximity Read ↗

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.Semantic proximity Read ↗

Biologic approaches to drug selection and targeted therapy: hype or clinical reality?Semantic proximity Read ↗

Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that Matter.Semantic proximity Read ↗

Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.Semantic proximity Read ↗

Current and future trends in non-small cell lung cancer biomarker testing: The American experience.Semantic proximity Read ↗

[Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].Semantic proximity Read ↗

Newly Diagnosed Lung Cancer: Which Molecular Tests Are Needed for Optimal Treatment Decision Making?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.